Celcuity (CELC) shares surged nearly 4% on Monday following the initiation of coverage by analyst Silvan Turkcan, who rated the stock as a market outperform with a price target of $150 per share. This target represents a nearly 20% upside from its recent closing price and highlights the growing optimism surrounding the biotech firm, particularly regarding its investigational drug gedatolisib, which targets advanced breast cancer.
The timing of this analyst coverage is critical, as the FDA is set to complete its review of Celcuity’s New Drug Application for gedatolisib in less than two months. Turkcan’s analysis suggests that the drug could not only gain approval for breast cancer but also for other indications, potentially enhancing its market value significantly. This positions Celcuity as a compelling opportunity in the biotech sector, especially given the heightened interest in oncology treatments.
For market professionals, Celcuity represents a high-risk, high-reward investment, particularly as the FDA decision approaches. The stock’s current valuation may be justified if gedatolisib receives approval, making it a noteworthy addition to biotech portfolios.
Source: fool.com